Table 1.
Targeted therapies for psoriatic arthritis.
| Therapy | Mechanism of Action |
|---|---|
| Infliximab | Chimeric monoclonal antibody against TNF-α |
| Etanercept | Soluble TNF receptor p75-immunoglobulin G1 fusion protein |
| Adalimumab | Fully human anti-TNF-α monoclonal antibody |
| Golimumab | Fully human immunoglobulin G1 kappa anti-TNF-α antibody |
| Certolizumab pegol |
Fab fragment of anti-TNF- α monoclonal antibody |
| Ustekinumab | Fully human immunoglobulin G1 kappa monoclonal antibody against the shared p40 subunit of IL-12 and IL-23 |
| Guselkumab | Fully human immunoglobulin G1 lambda monoclonal antibody against the p19 subunit of IL-23 |
| Risankizumab | Fully human immunoglobulin G1 lambda monoclonal antibody against the p19 subunit of IL-23 |
| Secukinumab | Fully human immunoglobulin G1 kappa monoclonal antibody against IL-17A |
| Ixekizumab | Humanised immunoglobulin G4 monoclonal antibody against IL-17A |
| Brodalumab | Fully human immunoglobulin G2 monoclonal antibody against IL-17RA |
| Bimekizumab | Humanised immunoglobulin G1 monoclonal antibody against IL-17A and IL-17F |
| Tofacitinib | Inhibitor of JAK1 and JAK3 |
| Upadacitinib | Selective inhibitor of JAK1 |
| Filgotinib | Selective inhibitor of JAK1 |
| Deucravacitinib | Selective TYK2 inhibitor |
| Abatacept | Selective T cell co-stimulator inhibitor |